Effects of Survivin on cell proliferation and apoptosis in MG-63 cells in vitro

Cell Biology International

Volumn 33, Issue 1, 2009, Pages 119-124

  Liang, Xinjun ^a   Da, Mingxu ^b   Zhuang, Zhiqiang ^a   Wu, Weiguang ^a   Wu, Zhuang ^a   Wu, Yanfeng ^a   Shen, Huiyong ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b GANSU PROVINCIAL HOSPITAL   (China)

Author keywords

Apoptosis; Osteosarcoma; Survivin

Indexed keywords

ANTINEOPLASTIC AGENT; ANTISENSE ENHANCED GROWTH FACTOR PROTEIN C1 SURVIVIN; SURVIVIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER INVASION; CELL PROLIFERATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; OSTEOSARCOMA; OSTEOSARCOMA CELL; PHENOTYPE; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

APOPTOSIS; BLOTTING, WESTERN; BONE NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DOWN-REGULATION; HUMANS; MICROTUBULE-ASSOCIATED PROTEINS; OLIGONUCLEOTIDES, ANTISENSE; OSTEOSARCOMA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; RNA, MESSENGER; TRANSFECTION;

EID: 57649210498     PISSN: 10656995     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cellbi.2008.10.013     Document Type: Article

References (40)

1. Ai Z., Yin L., Zhou X., Zhu Y., Zhu D., Yu Y., et al. Inhibition of survivin reduces cell proliferation and induces apoptosis in human endometrial cancer. Cancer 107 (2006) 746-756
2. Ambrosini G., Adida C., and Altieri D.C. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 3 (1997) 917-921
3. Bacci G., Briccoli A., Rocca M., Ferrari S., Donati D., Longhi A., et al. Neoadjuvant chemotherapy for osteosarcoma of the extremities with metastases at presentation: recent experience at the Rizzoli Institute in 57 patients treated with cisplatin, doxorubicin, and a high dose of methotrexate and ifosfamide. Ann Oncol 14 (2003) 1126-1134
4. Bacci G., Ferrari S., Mercuri M., Longhi A., Fabbri N., Galletti S., et al. Neoadjuvant chemotherapy for osteosarcoma of the extremities in patients aged 41-60 years: outcome in 34 cases treated with adriamycin, cisplatinum and ifosfamide between 1984 and 1999. Acta Orthop 78 (2007) 377-384
5. Carelli S., Lesma E., Paratore S., Grande V., Zadra G., Bosari S., et al. Survivin expression in tuberous sclerosis complex cells. Mol Med 13 (2007) 166-177
6. Chao J.I., Kuo P.C., and Hsu T.S. Down-regulation of survivin in nitric oxide-induced cell growth inhibition and apoptosis of the human lung carcinoma cells. J Biol Chem 279 (2004) 20267-20276
7. Cho H.J., Lee T.S., Park J.B., Park K.K., Choe J.Y., Sin D.I., et al. Disulfiram suppresses invasive ability of osteosarcoma cells via the inhibition of MMP-2 and MMP-9 expression. J Biochem Mol Biol 40 (2007) 1069-1076
8. Chou A.J., Merola P.R., Wexler L.H., Gorlick R.G., Vyas Y.M., Healey J.H., et al. Treatment of osteosarcoma at first recurrence after contemporary therapy: the Memorial Sloan-Kettering Cancer Center experience. Cancer 104 (2005) 2214-2221
9. Cohen C., Lohmann C.M., Cotsonis G., Lawson D., and Santoianni R. Survivin expression in ovarian carcinoma: correlation with apoptotic markers and prognosis. Mod Pathol 16 (2003) 574-583
10. DuBois S., and Demetri G. Markers of angiogenesis and clinical features in patients with sarcoma. Cancer 109 (2007) 813-819
11. Ganjavi H., Gee M., Narendran A., Parkinson N., Krishnamoorthy M., Freedman M.H., et al. Adenovirus-mediated p53 gene therapy in osteosarcoma cell lines: sensitization to cisplatin and doxorubicin. Cancer Gene Ther 13 (2006) 415-419
12. Gazzaniga P., Gradilone A., Giuliani L., Gandini O., Silvestri I., Nofroni I., et al. Expression and prognostic significance of LIVIN, SURVIVIN and other apoptosis-related genes in the progression of superficial bladder cancer. Ann Oncol 14 (2003) 85-90
13. Gordon G.J., Mani M., Mukhopadhyay L., Dong L., Edenfield H.R., Glickman J.N., et al. Expression patterns of inhibitor of apoptosis proteins in malignant pleural mesothelioma. J Pathol 211 (2007) 447-454
14. Graat H.C., van Beusechem V.W., Schagen F.H., Witlox M.A., Kleinerman E.S., Helder M.N., et al. Intravenous administration of the conditionally replicative adenovirus Ad5-Delta24RGD induces regression of osteosarcoma lung metastases. Mol Cancer 23 (2008) 9
15. Kager L., Zoubek A., Pötschger U., Kastner U., Flege S., Kempf-Bielack B., et al. Cooperative German-Austrian-Swiss Osteosarcoma Study Group. Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. J Clin Oncol 21 (2003) 2011-2018
16. Kappler M., Rot S., Taubert H., Greither T., Bartel F., Dellas K., et al. The effects of knockdown of wild-type survivin, survivin-2B or survivin-delta3 on the radiosensitization in a soft tissue sarcoma cells in vitro under different oxygen conditions. Cancer Gene Ther 14 (2007) 994-1001
17. Kersting C., Gebert C., Agelopoulos K., Schmidt H., van Diest P.J., Juergens H., et al. Epidermal growth factor receptor expression in high-grade osteosarcomas is associated with a good clinical outcome. Clin Cancer Res 13 (2007) 2998-3005
18. Kim M.S., Lee S.Y., Cho W.H., Song W.S., Koh J.S., Lee J.A., et al. Initial tumor size predicts histologic response and survival in localized osteosarcoma patients. J Surg Oncol 97 (2008) 456-461
19. Kishida Y., Yoshikawa H., and Myoui A. Parthenolide, a natural inhibitor of nuclear factor-kappaB, inhibits lung colonization of murine osteosarcoma cells. Clin Cancer Res 13 (2007) 59-67
20. Klein M.J., and Siegal G.P. Osteosarcoma: anatomic and histologic variants. Am J Clin Pathol 125 (2006) 555-581
21. LaCasse E.C., Baird S., Korneluk R.G., and MacKenzie A.E. The inhibitors of apoptosis (IAPs) and their emerging role in cancer. Oncogene 17 (1998) 3247-3259
22. Lamoureux F., Richard P., Wittrant Y., Battaglia S., Pilet P., Trichet V., et al. Therapeutic relevance of osteoprotegerin gene therapy in osteosarcoma: blockade of the vicious cycle between tumor cell proliferation and bone resorption. Cancer Res 67 (2007) 7308-7318
23. Lee R.S., Higgs D., Haddo O., Pringle J., and Briggs T.W. Osteosarcoma associated with diamond-blackfan anaemia: a case of a child receiving growth hormone therapy. Sarcoma 8 (2004) 47-49
24. Lee J.A., Kim M.S., Kim D.H., Lim J.S., Yoo J.Y., Koh J.S., et al. Relative tumor burden predicts metastasis-free survival in pediatric osteosarcoma. Pediatr Blood Cancer 50 (2008) 195-200
25. Ma X., Wang S., Zhou J., Xing H., Xu G., Wang B., et al. Induction of apoptosis in human ovarian epithelial cancer cells by antisurvivin oligonucleotides. Oncol Rep 14 (2005) 275-279
26. Okada K., Hasegawa T., Nishida J., Ogose A., Tajino T., Osanai T., et al. Osteosarcomas after the age of 50: a clinicopathologic study of 64 cases - an experience in northern Japan. Ann Surg Oncol 11 (2004) 998-1004
27. Osaka E., Suzuki T., Osaka S., Yoshida Y., Sugita H., Asami S., et al. Survivin as a prognostic factor for osteosarcoma patients. Acta Histochem Cytochem 39 (2006) 95-100
28. Osaka E., Suzuki T., Osaka S., Yoshida Y., Sugita H., Asami S., et al. Survivin expression levels as independent predictors of survival for osteosarcoma patients. J Orthop Res 25 (2007) 116-121
29. Paduano F., Villa R., Pennati M., Folini M., Binda M., Daidone M.G., et al. Silencing of survivin gene by small interfering RNAs produces supra-additive growth suppression in combination with 17-allylamino-17-demethoxygeldanamycin in human prostate cancer cells. Mol Cancer Ther 5 (2006) 179-186
30. Pratt M.A., Niu M.Y., and Renart L.I. Regulation of survivin by retinoic acid and its role in paclitaxel-mediated cytotoxicity in MCF-7 breast cancer cells. Apoptosis 11 (2006) 589-605
31. Rahman K.W., Li Y., Wang Z., Sarkar S.H., and Sarkar F.H. Gene expression profiling revealed survivin as a target of 3,3′-diindolylmethane-induced cell growth inhibition and apoptosis in breast cancer cells. Cancer Res 66 (2006) 4952-4960
32. Ryan B.M., Konecny G.E., Kahlert S., Wang H.J., Untch M., Meng G., et al. Survivin expression in breast cancer predicts clinical outcome and is associated with HER2, VEGF, urokinase plasminogen activator and PAI-1. Ann Oncol 17 (2006) 597-604
33. Stauber R.H., Mann W., and Knauer S.K. Nuclear and cytoplasmic survivin: molecular mechanism, prognostic, and therapeutic potential. Cancer Res 67 (2007) 5999-6002
34. Tanabe H., Yagihashi A., Tsuji N., Shijubo Y., Abe S., and Watanabe N. Expression of survivin mRNA and livin mRNA in non-small-cell lung cancer. Lung Cancer 46 (2004) 299-304
35. Trieb K., Lehner R., Stulnig T., Sulzbacher I., and Shroyer K.R. Survivin expression in human osteosarcoma is a marker for survival. Eur J Surg Oncol 29 (2003) 379-382
36. Troeger A., Siepermann M., Escherich G., Meisel R., Willers R., Gudowius S., et al. Survivin and its prognostic significance in pediatric acute B-cell precursor lymphoblastic leukemia. Haematologica 92 (2007) 1043-1050
37. Tu S.P., Jiang X.H., Lin M.C., Cui J.T., Yang Y., Lum C.T., et al. Suppression of survivin expression inhibits in vivo tumorigenicity and angiogenesis in gastric cancer. Cancer Res 63 (2003) 7724-7732
38. Wang W., Luo H., and Wang A. Expression of survivin and correlation with PCNA in osteosarcoma. J Surg Oncol 93 (2006) 578-584
39. Yamashita S., Masuda Y., Kurizaki T., Haga Y., Murayama T., Ikei S., et al. Survivin expression predicts early recurrence in early-stage breast cancer. Anticancer Res 27 (2007) 2803-2808
40. Zhou J., O'brate A., Zelnak A., and Giannakakou P. Survivin deregulation in beta-tubulin mutant ovarian cancer cells underlies their compromised mitotic response to taxol. Cancer Res 64 (2004) 8708-8714